Ipilimumab/Nivolumab Is the New Standard of Care in Metastatic Renal Cell Carcinoma

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2018年 / 16卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：11 / 12
页数：2
相关论文
共 50 条
  • [21] Three Cases of Nivolumab Plus Ipilimumab Therapy in Haemodialysis Patients With Metastatic Renal Cell Carcinoma
    Kobari, Yuki
    Yoshida, Kazuhiko
    Iizuka, Junpei
    Kondo, Tsunenori
    Ishida, Hideki
    Tanabe, Kazunari
    Takagi, Toshio
    IN VIVO, 2021, 35 (06): : 3585 - 3589
  • [22] Body composition in patients with metastatic renal cell carcinoma receiving ipilimumab plus nivolumab.
    Dzimitrowicz, Hannah Elizabeth
    Schwartz, Fides
    Infield, Jordan
    Zhang, Dylan
    Ho, Ethan
    Wu, Yuan
    Gupta, Rajan T.
    Harrison, Michael Roger
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16517 - E16517
  • [23] Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study
    Hammers, Hans J.
    Plimack, Elizabeth R.
    Infante, Jeffrey R.
    Rini, Brian I.
    McDermott, David F.
    Lewis, Lionel D.
    Voss, Martin H.
    Sharma, Padmanee
    Pal, Sumanta K.
    Razak, Albiruni R. Abdul
    Kollmannsberger, Christian
    Heng, Daniel Y. C.
    Spratlin, Jennifer
    McHenry, M. Brent
    Amin, Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (34) : 3851 - +
  • [24] COMPLETE CLINICAL AND HISTOLOGICAL RESPONSE TO COMBINATION NIVOLUMAB AND IPILIMUMAB IN A PATIENT WITH METASTATIC RENAL CELL CARCINOMA
    Pandey, Y.
    Matin, A.
    Kunthur, A.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2020, 68 (02) : 518 - 519
  • [25] Phase I study of nivolumab in combination with ipilimumab (IPI) in metastatic renal cell carcinoma (mRCC)
    Hammers, H.
    Plimack, E. R.
    Infante, J. R.
    Ernstoff, M. S.
    Rini, B.
    Mcdermott, D. F.
    Razak, A.
    Pal, S. K.
    Voss, M. H.
    Sharma, P.
    Kollmannsberger, C.
    Heng, D. Y. C.
    Spratlin, J.
    Shen, Y.
    Kurland, J. F.
    Gagnier, P.
    Amin, A.
    BJU INTERNATIONAL, 2014, 114 : 8 - 8
  • [26] Nivolumab plus ipilimumab in advanced renal-cell carcinoma
    Gunjur, Ashray
    LANCET ONCOLOGY, 2018, 19 (05): : E232 - E232
  • [27] Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
    Choueiri, Toni K.
    Powles, Thomas
    Albiges, Laurence
    Burotto, Mauricio
    Szczylik, Cezary
    Zurawski, Bogdan
    Ruiz, Eduardo Yanez
    Maruzzo, Marco
    Zaizar, Alberto Suarez
    Fein, Luis E.
    Schutz, Fabio A.
    Heng, Daniel Y. C.
    Wang, Fong
    Mataveli, Fabio
    Chang, Yu-Lin
    van Kooten Losio, Maximiliano
    Suarez, Cristina
    Motzer, Robert J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (19): : 1767 - 1778
  • [28] Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
    Beypinar, Ismail
    Araz, Murat
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (05): : 476 - 478
  • [29] Clinical Activity of Ipilimumab Plus Nivolumab in Patients With Metastatic Non- Clear Cell Renal Cell Carcinoma
    Gupta, Ruby
    Ornstein, Moshe Chaim
    Li, Hong
    Allman, Kimberly D.
    Wood, Laura S.
    Gilligan, Timothy
    Garcia, Jorge A.
    Von Merveldt, Dendra
    Hammers, Hans J.
    Rini, Brian I.
    CLINICAL GENITOURINARY CANCER, 2020, 18 (06) : 429 - 435
  • [30] Baseline neutrophil-to-eosinophil-ratio and outcome in metastatic clear-cell renal cell carcinoma treated with nivolumab or ipilimumab/nivolumab
    Beulque, Yana
    Kinget, Lisa
    Roussel, Eduard
    Mobaraki, Sajedeh
    Laenen, Annouschka
    Debruyne, Philip R.
    Van Herck, Yannick
    Baldewijns, Marcella
    Wozniak, Agnieszka
    Garg, Abhishek D.
    Zucman-Rossi, Jessica
    Couchy, Gabrielle
    Albersen, Maarten
    De Wever, Liesbeth
    Haaker, Lorenz
    Beuselinck, Benoit
    ACTA ONCOLOGICA, 2024, 63 : 658 - 668
12345